Search research articles
Contact Us
Filters
Showing results (91-100 of 118) with videos related to
Page
of 12
Sort By:
Anticancer Research
|
October 28, 2015
Antitumor Activity of 3-Indolylmethanamines 31B and PS121912
Margaret L Guthrie, Preetpal S Sidhu, Emily K Hill, et al.
Plos One
|
April 18, 2012
Efficacy of a non-hypercalcemic vitamin-D2 derived anti-cancer agent (MT19c) and inhibition of fatty acid synthesis in an ovarian cancer xenograft model
Richard G Moore, Thilo S Lange, Katina Robinson, et al.
Genes & Cancer
|
January 4, 2014
PT19c, Another Nonhypercalcemic Vitamin D2 Derivative, Demonstrates Antitumor Efficacy in Epithelial Ovarian and Endometrial Cancer Models
Nada Kawar, Shannon Maclaughlan, Timothy C Horan, et al.
Scientific Reports
|
June 4, 2024
In silico predicted compound targeting the IQGAP1-GRD domain selectively inhibits growth of human acute myeloid leukemia
Deepak M Sahasrabudhe, Jane L Liesveld, Mohammad Minhajuddin, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 1, 2024
Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study
Whitney S Graybill, Beatriz Pardo Búrdalo, David M O'Malley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 26, 2021
A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response
Linda R Duska, Virginia L Filiaci, Joan L Walker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 14, 2023
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775
Vicky Makker, Nicoletta Colombo, Antonio Casado Herráez, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 29, 2025
Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study
Whitney S Graybill, Beatriz Pardo Búrdalo, David M O'Malley, et al.
Gynecologic Oncology
|
June 4, 2024
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Giorgio Valabrega, Bhavana Pothuri, Ana Oaknin, et al.
American Journal of Obstetrics and Gynecology
|
August 11, 2018
Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study
Ashley S Felix, David E Cohn, Theodore M Brasky, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 118) with videos related to
Sort By:
Page
of 12
Anticancer Research
|
October 28, 2015
Antitumor Activity of 3-Indolylmethanamines 31B and PS121912
Margaret L Guthrie, Preetpal S Sidhu, Emily K Hill, et al.
Plos One
|
April 18, 2012
Efficacy of a non-hypercalcemic vitamin-D2 derived anti-cancer agent (MT19c) and inhibition of fatty acid synthesis in an ovarian cancer xenograft model
Richard G Moore, Thilo S Lange, Katina Robinson, et al.
Genes & Cancer
|
January 4, 2014
PT19c, Another Nonhypercalcemic Vitamin D2 Derivative, Demonstrates Antitumor Efficacy in Epithelial Ovarian and Endometrial Cancer Models
Nada Kawar, Shannon Maclaughlan, Timothy C Horan, et al.
Scientific Reports
|
June 4, 2024
In silico predicted compound targeting the IQGAP1-GRD domain selectively inhibits growth of human acute myeloid leukemia
Deepak M Sahasrabudhe, Jane L Liesveld, Mohammad Minhajuddin, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 1, 2024
Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study
Whitney S Graybill, Beatriz Pardo Búrdalo, David M O'Malley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 26, 2021
A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response
Linda R Duska, Virginia L Filiaci, Joan L Walker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 14, 2023
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775
Vicky Makker, Nicoletta Colombo, Antonio Casado Herráez, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 29, 2025
Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study
Whitney S Graybill, Beatriz Pardo Búrdalo, David M O'Malley, et al.
Gynecologic Oncology
|
June 4, 2024
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Giorgio Valabrega, Bhavana Pothuri, Ana Oaknin, et al.
American Journal of Obstetrics and Gynecology
|
August 11, 2018
Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study
Ashley S Felix, David E Cohn, Theodore M Brasky, et al.
Page
of 12